Thomas Schall - ChemoCentryx Founder, Chairman, CEO and Pres
CCXIDelisted Stock | USD 51.99 0.00 0.00% |
Chairman
Dr. Thomas J. Schall, Ph.D., is the Chairman of the Board, President, Chief Executive Officer of ChemoCentryx, From 1993 to March 1997, Dr. Schall worked at the DNAX Research Institute, a division of ScheringPlough Corporationrationration, a pharmaceutical company. Prior to his work at the DNAX Research Institute, he worked as a scientist with Genentech, Inc., a pharmaceutical company. Dr. Schall participated in some of the earliest discoveries of chemokine system function and activities. Dr. Schall cloned one of the first chemokines to be discovered, and provided some of the earliest data for the existence of the previously unknown family of molecules which later came to be called the chemokines. Dr. Schalls laboratories have been responsible for the discovery or codiscovery of almost onethird of all known chemokine receptors since 2012.
Age | 58 |
Tenure | 12 years |
Professional Marks | Ph.D |
Phone | 650 210-2910 |
Web | www.chemocentryx.com |
ChemoCentryx Management Efficiency
The company has return on total asset (ROA) of (18.55) % which means that it has lost $18.55 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (46.96) %, meaning that it created substantial loss on money invested by shareholders. ChemoCentryx's management efficiency ratios could be used to measure how well ChemoCentryx manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 73.2 M in liabilities with Debt to Equity (D/E) ratio of 0.31, which is about average as compared to similar companies. ChemoCentryx has a current ratio of 4.45, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist ChemoCentryx until it has trouble settling it off, either with new capital or with free cash flow. So, ChemoCentryx's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like ChemoCentryx sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for ChemoCentryx to invest in growth at high rates of return. When we think about ChemoCentryx's use of debt, we should always consider it together with cash and equity.
Similar Executives
Found 11 records | CHAIRMAN Age | ||
John Thornton | Barrick Gold Corp | 70 | |
Thomas Reddin | Asbury Automotive Group | 60 | |
Gregory Ebel | Sea | 50 | |
Graham Shuttleworth | Barrick Gold Corp | 55 | |
Tadashi Yanai | Fast Retailing Co | 74 | |
Thomas DeLoach | Asbury Automotive Group | 73 | |
Xiaodong Li | Sea | 46 | |
MA BA | Ioneer Ltd American | 66 | |
Forrest Li | Sea | N/A | |
Li Xiaodong | Sea | 42 | |
Christopher Coleman | Barrick Gold Corp | 51 |
Management Performance
Return On Equity | -46.96 | |||
Return On Asset | -18.55 |
ChemoCentryx Leadership Team
Elected by the shareholders, the ChemoCentryx's board of directors comprises two types of representatives: ChemoCentryx inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ChemoCentryx. The board's role is to monitor ChemoCentryx's management team and ensure that shareholders' interests are well served. ChemoCentryx's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ChemoCentryx's outside directors are responsible for providing unbiased perspectives on the board's policies.
Israel Charo, Senior Vice President - Research | ||
Jan Hillson, Senior Vice President - Drug Development | ||
Geoffrey Parker, Independent Director | ||
Susan Kanaya, CFO, Sr. VP of Fin. and Secretary | ||
Petrus Bekker, Senior Vice President - Clinical and Medical Affairs | ||
Joseph Feczko, Independent Director | ||
Markus Cappel, Chief Bus. Officer and Treasurer | ||
William Fairey, COO, Executive Vice President | ||
Thomas Edwards, Independent Director | ||
James Tyree, Independent Director | ||
Henry McKinnell, Director | ||
Rajinder Singh, Senior Vice President - Research | ||
Roger Lucas, Lead Independent Director | ||
Rita Jain, Independent Director | ||
Thomas Schall, Founder, Chairman, CEO and Pres |
ChemoCentryx Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ChemoCentryx a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -46.96 | |||
Return On Asset | -18.55 | |||
Operating Margin | (353.17) % | |||
Current Valuation | 3.45 B | |||
Shares Outstanding | 70.03 M | |||
Shares Owned By Insiders | 12.01 % | |||
Shares Owned By Institutions | 84.39 % | |||
Number Of Shares Shorted | 7.61 M | |||
Price To Earning | 40.53 X | |||
Price To Book | 10.04 X |
Pair Trading with ChemoCentryx
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ChemoCentryx position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ChemoCentryx will appreciate offsetting losses from the drop in the long position's value.Moving together with ChemoCentryx Stock
0.81 | REGN | Regeneron Pharmaceuticals Financial Report 2nd of May 2024 | PairCorr |
Moving against ChemoCentryx Stock
0.66 | GFGY | Granite Falls Energy | PairCorr |
0.58 | WXIBF | WuXi Biologics | PairCorr |
0.56 | PRSEF | Prosafe | PairCorr |
0.47 | FINN | First National | PairCorr |
0.44 | AMKBF | AP Mller - | PairCorr |
The ability to find closely correlated positions to ChemoCentryx could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ChemoCentryx when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ChemoCentryx - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ChemoCentryx to buy it.
The correlation of ChemoCentryx is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ChemoCentryx moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ChemoCentryx moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ChemoCentryx can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Other Consideration for investing in ChemoCentryx Stock
If you are still planning to invest in ChemoCentryx check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ChemoCentryx's history and understand the potential risks before investing.
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets |